CDTX:NSD-Cidara Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.40

Change

+0.26 (+12.15)%

Market Cap

USD 0.09B

Volume

0.31M

Average Target Price

USD 7.50 (+212.50%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.74 (-3.01%)

USD62.38B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.45 (+0.64%)

USD58.99B 22.23 17.39
REGN Regeneron Pharmaceuticals, Inc

-6.39 (-1.28%)

USD53.23B 18.28 14.53
SGEN Seagen Inc

-0.93 (-0.52%)

USD32.25B 68.04 62.62
BNTX BioNTech SE

+1.32 (+1.11%)

USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.55 (-0.45%)

USD26.49B 28.09 26.92
RPRX Royalty Pharma plc

+0.68 (+1.61%)

USD26.44B 22.60 9.98
GMAB Genmab A/S

+0.10 (+0.26%)

USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

+1.57 (+0.71%)

USD20.63B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.50% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.50% 21% F 10% F
Trailing 12 Months  
Capital Gain -9.09% 36% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.09% 36% F 30% F
Trailing 5 Years  
Capital Gain -85.82% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.82% 22% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -19.86% N/A N/A 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.86% N/A N/A 10% F
Risk Return Profile  
Volatility (Standard Deviation) 51.78% N/A N/A 21% F
Risk Adjusted Return -38.36% N/A N/A 17% F
Market Capitalization 0.09B 24% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.42 58% F 40% F
Price / Cash Flow Ratio -3.30 34% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -164.30% 15% F 6% F
Return on Invested Capital -71.40% 42% F 13% F
Return on Assets -55.36% 13% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.25 47% F 31% F
Short Percent 4.08% 65% D 43% F
Beta 1.66 41% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector